Retension Pharmaceuticals, Inc. — Form 10-Q
Filed November 18, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Eric Keller (CEO) and Alex Schwartz (CFO) signed routine Sarbanes-Oxley Sections 302 and 906 certifications on November 18, 2026, attesting to the accuracy of Retension Pharmaceuticals' Q3 2026 10-Q and the effectiveness of disclosure controls and internal financial reporting. No material weaknesses, deficiencies, or fraud disclosures were noted in the certifications.
Why this rating
Boilerplate executive certification exhibits; absence of internal control warnings is mildly positive but routine for compliant filers.
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.